Top

Published in:

01-10-2014

Predicting regression of Barrett’s esophagus: results from a retrospective cohort of 1342 patients

Authors: Craig S. Brown, Brittany Lapin, Chi Wang, Jay L. Goldstein, John G. Linn, Woody Denham, Stephen P. Haggerty, Mark S. Talamonti, John A. Howington, Joann Carbray, Michael B. Ujiki

Published in: Surgical Endoscopy | Issue 10/2014

Abstract

Introduction

Barrett’s esophagus (BE) is the most predictive risk factor for development of esophageal adenocarcinoma (EAC), a malignancy with the fastest increasing incidence in the US. The aim of this study was to investigate differences in exposures, demographics, and comorbidities between regressing and non-regressing patients.

Methods and procedures

We retrospectively collected and analyzed data from a cohort of BE patients participating in a single-center study comprised of all patients diagnosed with BE over a 10-year period. We collected information from the patient’s electronic medical records regarding demographic data, endoscopic findings, histological findings, exposures, and history of antireflux surgery.

Results

This study included 1,342 BE patients, 505 (37.6 %) of which experienced regression. The regressed group was 52.3 % male, while the non-regressing group was 68.3 % male (p < 0.001). Mean age was 65.2 ± 12.8 and 62.0 ± 13.1 years for non-regressing and regressing patients, respectively (p < 0.001). No difference was seen in BMI between regressing and non-regressing groups (27.5 ± 5.7 vs. 27.7 ± 5.4, p = 0.52). No difference was seen between groups with respect to PPI use (93.5 % non-regressing vs. 94.1 % regressed patients, p = 0.70), but regressed patients were more likely to take vitamin D than non-regressing patients (34.1 vs. 42.1 %, p = 0.003). Regressed patients had an average segment length of 1.48 cm (±1.58 cm), in contrast to those not regressing (3.58 ± 3.09 cm (p < 0.001)). Interestingly, one patient in the regression group progressed to dysplasia, while 101 of the non-regressing patients progressed to dysplasia/EAC, a result found to be independent of segment length on multivariate analysis (p < 0.001).

Conclusions

Currently, several studies have shown risk factors that can predict progression of non-dysplastic BE, but few investigate predictors for regression. Our study reports several factors that can be used to predict patients who will regress from BE and those who likely will not, tools that will be useful in tailoring therapeutic and surveillance strategies.

Sobieraj DM, Coleman SM, Coleman CI (2011) US prevalence of upper gastrointestinal symptoms: a systematic literature review. Am J Manag Care 17:e449–e458PubMed

Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P (2012) Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 107:1655–1661PubMedCrossRef

Sihvo EI, Luostarinen ME, Salo JA (2004) Fate of patients with adenocarcinoma of the esophagus and the esophagogastric junction: a population-based analysis. Am J Gastroenterol 99:419–424PubMedCrossRef

Polednak AP (2003) Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 105:98–100PubMedCrossRef

Lepage C, Rachet B, Jooste V, Faivre J, Coleman MP (2008) Continuing rapid increase in esophageal adenocarcinoma in England and Wales. Am J Gastroenterol 103:2694–2699PubMedCrossRef

Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049–2053PubMedCrossRef

Crane SJ, Locke GR 3rd, Harmsen WS, Zinsmeister AR, Romero Y, Talley NJ (2008) Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clinic Proc 83:1087–1094CrossRef

Dulai GS, Shekelle PG, Jensen DM, Spiegel BM, Chen J, Oh D, Kahn KL (2005) Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett’s cohort. Am J Gastroenterol 100:775–783PubMedCrossRef

Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ (2011) Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 103:1049–1057PubMedCrossRefPubMedCentral

10.

Kong CY, Nattinger KJ, Hayeck TJ, Omer ZB, Wang YC, Spechler SJ, McMahon PM, Gazelle GS, Hur C (2011) The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomark Prev 20:2450–2456CrossRef

11.

Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, Feuer EJ (2013) Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119:1149–1158PubMedCrossRefPubMedCentral

12.

Jo HJ, Lee HS, Kim N, Nam RH, Chang H, Kim MS, Kim SE, Oh JC, Lee DH, Jung HC (2013) Predictable marker for regression of Barrett’s esophagus by proton pump inhibitor treatment in Korea. J Neurogastroenterol Motil 19:210–218PubMedCrossRefPubMedCentral

13.

Weston AP, Badr AS, Hassanein RS (1999) Prospective multivariate analysis of factors predictive of complete regression of Barrett’s esophagus. Am J Gastroenterol 94:3420–3426PubMedCrossRef

14.

Horwhat JD, Baroni D, Maydonovitch C, Osgard E, Ormseth E, Rueda-Pedraza E, Lee HJ, Hirota WK, Wong RK (2007) Normalization of intestinal metaplasia in the esophagus and esophagogastric junction: incidence and clinical data. Am J Gastroenterol 102:497–506PubMedCrossRef

15.

Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard CJ, Kingsnorth AN (1995) Regression and progression of Barrett’s oesophagus after antireflux surgery. Br J Surg 82:806–810PubMedCrossRef

16.

Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MW, Shepherd NA, Wilkinson SP (1993) Regression of columnar lined (Barrett’s) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 7:623–628PubMedCrossRef

17.

Sampliner RE (1994) Effect of up to 3 years of high-dose lansoprazole on Barrett’s esophagus. Am J Gastroenterol 89:1844–1848PubMed

18.

Neumann CS, Iqbal TH, Cooper BT (1995) Long term continuous omeprazole treatment of patients with Barrett’s oesophagus. Aliment Pharmacol Ther 9:451–454PubMedCrossRef

19.

Malesci A, Savarino V, Zentilin P, Belicchi M, Mela GS, Lapertosa G, Bocchia P, Ronchi G, Franceschi M (1996) Partial regression of Barrett’s esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 44:700–705PubMedCrossRef

20.

Montgomery E, Bronner MP, Goldblum JR, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Toledano AY, Shyr Y, Washington K (2001) Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol 32:368–378PubMedCrossRef

21.

Corley DA, Kubo A, Levin TR, Block G, Habel L, Rumore G, Quesenberry C, Buffler P (2009) Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut 58:182–188PubMedCrossRefPubMedCentral

22.

Lofdahl HE, Lu Y, Lagergren J (2008) Sex-specific risk factor profile in oesophageal adenocarcinoma. Br J Cancer 99:1506–1510PubMedCrossRefPubMedCentral

23.

Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 99:860–868PubMedCrossRef

24.

de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ (2010) Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut 59:1030–1036PubMedCrossRef

25.

Bodelon C, Anderson GL, Rossing MA, Chlebowski RT, Ochs-Balcom HM, Vaughan TL (2011) Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. Cancer Prev Res (Phila) 4:840–850CrossRef

26.

Andrici J, Tio M, Cox MR, Eslick GD (2013) Hiatal hernia and the risk of Barrett’s esophagus. J Gastroenterol Hepatol 28:415–431PubMedCrossRef

27.

Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ (2002) Hiatal hernia size, Barrett’s length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol 97:1930–1936PubMedCrossRef

28.

Mulholland HG, Murray LJ, Anderson LA, Cantwell MM (2011) Vitamin D, calcium and dairy intake, and risk of oesophageal adenocarcinoma and its precursor conditions. Br J Nutr 106:732–741PubMedCrossRef

29.

Guda NM, Partington S, Vakil N (2004) Inter- and intra-observer variability in the measurement of length at endoscopy: implications for the measurement of Barrett’s esophagus. Gastrointest Endosc 59:655–658PubMedCrossRef

Title: Predicting regression of Barrett’s esophagus: results from a retrospective cohort of 1342 patients
Authors: Craig S. Brown
Brittany Lapin
Chi Wang
Jay L. Goldstein
John G. Linn
Woody Denham
Stephen P. Haggerty
Mark S. Talamonti
John A. Howington
Joann Carbray
Michael B. Ujiki
Publication date: 01-10-2014
Publisher: Springer US
Published in: Surgical Endoscopy / Issue 10/2014
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-014-3548-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Predicting regression of Barrett’s esophagus: results from a retrospective cohort of 1342 patients

Abstract

Introduction

Methods and procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods and procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes

Should technical aptitude evaluation become part of resident selection for surgical residency?

Laparoscopic resection of large gastric GISTs: feasibility and long-term results

Impact of a hands-on component on learning in the Fundamental Use of Surgical Energy™ (FUSE) curriculum: a randomized-controlled trial in surgical trainees

A meta-analysis of robotic versus laparoscopic gastrectomy for gastric cancer

An extended proximal esophageal myotomy is necessary to normalize EGJ distensibility during Heller myotomy for achalasia, but not POEM